Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moERTAPENEM SODIUM (ertapenem) by Gland Pharma is 12. Approved for older) with complicated intra-abdominal infections due to escherichia coli, clostridium clostridioforme, eubacterium lentum and 24 more indications. First approved in 2018.
Drug data last refreshed 22h ago
12.1 Mechanism of Action Ertapenem sodium is a carbapenem antibiotic [see ]. 12.3 Pharmacokinetics Average plasma concentrations (mcg/mL) of ertapenem following a single 30-minute infusion of a 1 g intravenous (IV) dose and administration of a single 1 g intramuscular (IM) dose in healthy young…
Worked on ERTAPENEM SODIUM at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo